|Bid||29.25 x 0|
|Ask||29.30 x 0|
|Day's range||27.30 - 29.50|
|52-week range||13.85 - 29.50|
|PE ratio (TTM)||N/A|
|Earnings date||28 Mar 2018 - 2 Apr 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||16.22|
Jan 9 (Reuters) - Acer Inc: * SAYS DEC SALES UP 11.6 PERCENT Y/Y AT T$21.0 BILLION ($711.60 million) Source text in Chinese: http://bit.ly/2FgfmKy Further company coverage: ($1 = 29.5110 Taiwan dollars) ...
NEWTON, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that Chris Schelling, CEO and Founder, will provide a corporate overview at the Biotech Showcase™ Conference, being held January 8-10, 2018 in San Francisco.
Acer Therapeutics Inc. (Nasdaq:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and ultra-rare diseases with critical unmet medical need, today announced that the underwriters of its previously announced public offering of common stock have partially exercised their over-allotment option by the purchase of an additional 130,000 shares at a price to the public of $12.00 per share, resulting in additional gross proceeds of $1.56 million, before deducting underwriting discounts and commissions and other offering expenses payable by Acer. After giving effect to the partial exercise of the over-allotment option, the total number of shares sold by Acer in the offering increased to 1,046,667 shares and the total gross proceeds increased to $12.56 million.
Acer Inc. is attracting the interest of stock investors again, after spending years in the doldrums as its share price collapsed along with PC sales.
Hexagon chief executive Ola Rollen's knowledge that Next Biometrics had signed a major client when he made an investment in the Norwegian company was not material, an Oslo court was told on Monday. Rollen, who denies wrongdoing, is on trial for alleged insider trading related to a 2015 investment in Next Biometrics through Greenbridge, his part-owned investment firm, which is the biggest investor in the company with a 17 percent stake. During his testimony at Oslo's district court, Next Biometrics' former CEO Tore Etholm-Idsoee, who is now its acting chairman, said the essential information about the major client Next Biometrics had won was already known in the stockmarket.
Nov 9 (Reuters) - Acer Inc * Says Oct sales up 11.7 percent y/y Source text in Chinese: http://bit.ly/29I3zX1 Further company coverage: (Reporting by Hong Kong newsroom)
Nov 9 (Reuters) - Acer Inc * Says Q3 profit after tax at T$1.45 billion ($48.07 million) * Says Q3 consolidated revenues at T$60.6 billion * Says 9-month profit after tax at T$1.76 billion * Says 9-month ...